Harmony Biosciences subsidiary extends expiration of offer to acquire Zynerba

In connection with the previously announced merger agreement, Harmony Biosciences Holdings(HRMY) announced that Xylophone Acquisition, a wholly owned subsidiary of Harmony, has extended the expiration of its tender offer to acquire all of the outstanding shares of common stock of Zynerba Pharmaceuticals (ZYNE) to 5:00 p.m., New York City time, on Tuesday, October 10, unless further extended. The tender offer was previously scheduled to expire at 5:00 p.m., New York City time, on Tuesday, September 26. All other terms and conditions of the tender offer remain unchanged. The depositary for the tender offer has advised that, as of 5:00 p.m., New York City time, on Tuesday, September 26, a total of 17,298,313 shares of Zynerba’s common stock were validly tendered and not withdrawn in the tender offer, which represent approximately 32.1% of the total number of shares of Zynerba’s outstanding common stock.